Browsing by Author Reck, Martin

Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)TypePreview
2018Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerGandhi, Leena; Rodríguez-Abreu, Delvys; Gadgeel, Shirish M.; Esteban, Emilio; Felip, Enriqueta, et alArtículo
2018KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLCGandhi, Leena; Rodgriguez-Abreu, Delvys; Gadgeel, Shirish; Esteban, Emilio; Felip, Enriqueta, et alActas de congresos
2019Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical TrialMichels, Sebastian; Massutí, Bartomeu; Schildhaus, Hans Ulrich; Franklin, Jeremy; Sebastian, Martin, et alArtículo1-s2.0-S155608641930276X-main.pdf.jpg
2019IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutationsCurioni-Fontecedro, Alessandra; Mok, Tony; Socinski, Mark A.; Reck, Martin; Jotte, Robert M., et alActas de congresos
2019Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greaterReck, Martin; Rodríguez Abreu, Delvys; Robinson, Andrew G.; Hui, Rina; Csoszi, Tibor, et alArtículo
2019Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 studyGarassino, Marina C.; Gadgeel, Shirish; Esteban, Emilio; Felip, Enriqueta; Speranza, Giovanna, et alActas de congresos
2019KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.Gadgeel, Shirish M.; Garassino, Marina Chiara; Esteban, Emilio; Speranza, Giovanna; Felip, Enriqueta, et alActas de congresos
2020Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialGarassino, Marina C.; Gadgeel, Shirish; Esteban, Emilio; Felip, Enriqueta; Speranza, Giovanna, et alArtículo